Photo by nci from unsplash
Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence. Therefore, continued anticoagulant therapy beyond the initial 6 months is suggested in this patient population, but… Click to show full abstract
Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence. Therefore, continued anticoagulant therapy beyond the initial 6 months is suggested in this patient population, but evidence supporting this approach is limited.
Keywords:
vte;
venous thromboembolism;
cancer;
extended treatment;
treatment edoxaban
Journal Title: Journal of Thrombosis and Haemostasis
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Thrombosis and Haemostasis
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!